Compare Alcon AG (ALC) vs Boeing Co (BA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Boeing Co — how do they compare? Alcon AG trades at $66.84 (market cap $32.69B), while Boeing Co trades at $224.1 (market cap $182.63B). The key difference: Boeing Co is far larger — about 5.6× Alcon AG's market cap, and Alcon AG pays the higher dividend (0.54%). Which is the better fit depends on your goals.
| ALC | BA | |
|---|---|---|
Market Cap | $32.69B | $182.63B |
Sector | Health | Industrials |
52-Week High | $92.22 | $252.15 |
52-Week Low | $62.02 | $179.12 |
Enterprise Value | $36.28B | $208.94B |
Dividend Yield | 0.54% | 0.03% |
Volume | — | 7,591,579 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Boeing (BA) trades at $231.68, up 2.29% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $268.33. The company returned to profitability in 2025 with $2.24B net income on $89.46B revenue, though valuation ratios like P/E of 92.7 remain elevated. Recent news highlights defense contract wins and production expansion, including a new 737 assembly line.
Outlook: Boeing's recovery trajectory offers upside potential driven by operational improvements and strong backlog, but high debt, thin margins, and execution risks pose challenges. Analyst sentiment is predominantly bullish, yet investors should weigh valuation concerns against growth catalysts in the aerospace cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Boeing Co
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →
